Néovacs has announced a €1 million capital increase through the issue of 1 tranche of OCEANE-BSA bonds, with a par value of €1,000,000, subscribed by the European High Growth Opportunities Securitization Fund.

The net proceeds of this transaction (E960,000) will be used 50% to finance the Kinoïde® allergy research program, and 50% to strengthen the company's capacity to invest in promising projects, both in the development of drug candidates (BioTech) and medical devices (MedTech).

The drawdown of 1 tranche of OCEANE-BSA announced today gives rise to the issue of 114,942,528 warrants, which will be retroceded to Neovacs for cancellation, and could result in the creation of 283,687,943 new shares based on the last quoted price.

Copyright (c) 2023 CercleFinance.com. All rights reserved.